clinical trial

[LAVA Therapeutics, N.V.] LAVA Therapeutics N.V. announced dosing of the first patient in the company’s Phase I/IIa clinical trial of LAVA-051 in patients with relapsed and/or refractory chronic lymphocytic leukemia, multiple myeloma and acute myeloid leukemia.

[Blood] Advances in genomic sequencing, increased understanding of hemoglobin regulation and discoveries of molecular tools for genome modification of hematopoietic stem cells have made gene therapy for sickle cell disease possible. These therapies need to be portable, safe and efficient to make an in vivo based approach attractive.

[CytoDyn, Inc.] CytoDyn, Inc., a biotechnology company developing leronlimab, a CCR5 antagonist, announced its clinical trial with leronlimab in combination with carboplatin for the treatment of metastatic TNBC has advanced from Phase Ib to a Phase II trial.

[Nature Medicine] Researchers showed that engineering of a medium-length CAR spacer enhances the therapeutic efficacy of human erb-b2 receptor tyrosine kinase 2 (HER2)-specific CAR T cells in an orthotopic xenograft medulloblastoma model.

[Tevogen Bio (BusinessWire, Inc.)] Tevogen Bio, a clinical stage biotechnology company, announced that the FDA has cleared its Investigational New Drug application for TVGN-489, Allogeneic COVID-19 Specific Cytotoxic T Lymphocytes, allowing Tevogen Bio to initiate a clinical trial of its investigational COVID-19 treatment.

[Cell Death & Disease] Ectopic expression and knockdown experiments indicated that MYBL2 was essential for colorectal cell proliferation, DNA synthesis, and cell cycle progression in an ribonucleotide reductase small subunit M2 (RRM2)-dependent manner.